Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
暂无分享,去创建一个
J. Barberà | H. Ghofrani | A. Frost | G. Simonneau | M. Hoeper | V. McLaughlin | L. Rubin | J. Vachiéry | A. Peacock | C. Blair | K. Miller | N. Galiè | J. Langley | J. Vachiéry
[1] Y. Lacasse,et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. , 2016, The Lancet. Respiratory medicine.
[2] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[3] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[4] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[5] Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning , 2015, European Respiratory Journal.
[6] H. Ghofrani,et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.
[7] R. Benza,et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[8] E. Hunsche,et al. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. , 2015, The American journal of managed care.
[9] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[10] Guideline on clinical investigation of medicinal products for the treatment of acute heart failure , 2015 .
[11] A. Torbicki,et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. , 2015, JACC. Heart failure.
[12] M. Humbert,et al. The role of combination therapy in managing pulmonary arterial hypertension , 2014, European Respiratory Review.
[13] M. Mcgoon,et al. Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.
[14] M. Humbert,et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.
[15] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[16] P. Gargiulo,et al. Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension , 2012, European Respiratory Journal.
[17] P. Gargiulo,et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.
[18] M. Humbert,et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[19] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[20] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.